At 6.8% CAGR, the Asia Pacific Bromelain Market is Projected to be Worth US$ 23.36 million by 2030, Says Business Market Insights

According to Business Market Insights research, the Asia Pacific bromelain market was valued at US$ 13.75 million in 2022 and is expected to reach US$ 23.36 million by 2030, registering a CAGR of 6.8% from 2022 to 2030. Rising preference for natural plant-based ingredients and broad application scope in the food industry are among the critical factor attributed to the Asia Pacific bromelain market expansion.

Bromelain is used in the pharmaceutical industry as an anti-tumorigenic, anti-inflammatory, and anti-thrombotic agent. Moreover, it can prevent diseases such as bronchitis, sinusitis, and thrombophlebitis. It has been studied for its platelet aggregation inhibition, anti-edematous, anti-thrombotic, and fibrinolytic activities. It is also known for its ability to aid in digestion and wound-healing enhancement. Owing to these therapeutic actions, it is extensively used in pharmaceutical formulas and health supplements. The growing focus on maintaining optimum digestive and gut health boosts the demand for bromelain in dietary supplement manufacturing.

Bromelain is also applied in treating inflammation and swelling of the nose and sinuses after an injury or surgery. The anti-inflammatory and analgesic properties of bromelain make it an effective treatment for pain, soft tissue swelling, and joint stiffness associated with osteoarthritis. Bromelain improves functionality and decreases pain in mild acute knee pain and osteoarthritis. According to the World Health Organization (WHO), nearly 528 million people worldwide were living with osteoarthritis in 2019, recording an increase of 113% since 1990. Therefore, the rising applications of bromelain in the pharmaceutical & nutraceutical industries fuels the market growth.

On the contrary, high production cost hamper the growth Asia Pacific bromelain market .

Based on source, the Asia Pacific bromelain market is segmented into stem and fruit. The stem market segment held 78.5% share of the Asia Pacific bromelain market in 2022, amassing US$ 10.79 million. It is projected to garner US$ 18.10 million by 2030 to expand at 6.7% CAGR during 2022-2030.

By end user, the Asia Pacific bromelain market is categorized into food & beverages, pharmaceuticals & nutraceuticals, personal care, and others. The pharmaceuticals & nutraceuticals segment held 38.9% share of Asia Pacific bromelain market in 2022, amassing US$ 5.35 million. It is projected to garner US$ 8.62 million by 2030 to expand at 6.1% CAGR during 2022-2030.

Based on country, the Asia Pacific bromelain market is categorized into China, India, Japan, Australia, South Korea, and the Rest of the Asia Pacific. The Rest of the Asia Pacific held 32.1% share of Asia Pacific bromelain market in 2022, amassing US$ 4.41 million. It is projected to garner US$ 7.04 million by 2030 to expand at 6.0% CAGR during 2022-2030.

Key players operating in the Asia Pacific bromelain market are Antozyme Biotech Pvt Ltd, Challenge Bioproducts Co Ltd, Changsha Natureway Co Ltd, Creative Enzymes, Enzybel International SA, Great Food (Biochem) Co Ltd, Guangxi Nanning Javely Biological Products Co Ltd, Hong Mao Biochemicals Co Ltd, and Medikonda Nutrients, among others.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com